Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9039)	9/2/2003 11:24:50 PM
From: A.J. Mullen	Respond to of 52153

I hesitate to respond on this thread to interest in MYGN, but I should put my mouth where my money is. I like the idea of tailoring treatment to the genetic make-up. I think analysts over-reacted to the slowed increase in predictive medicine. The tests are expensive - even with insurance. Cancer is a nebulous threat until diagnosed. If money is tight then that provides another reason for procrastination. In the conference call, presenters seemed upbeat about both the AIDs drug and the prostate, but were not suggesting any short-term announcements - quite the reverse. It is worrying though that my post after a call in August reads very much like the one (on a different thread) after a call in February. Ashley

To: Biomaven who wrote (9039)	9/3/2003 8:33:44 AM
From: nigel bates	Respond to of 52153

Maybe I should start a new biotech thread "Where are they now?" No <g> necessary - it's a good idea. In sharp contrast, an interesting article in the Times today features an interview with the ceo of Vernalis. They are reviewing the combined "product portfolio", and "substantially more than half" of it is going to be canned to conserve cash. Good to see the knife being wielded publicly. Makes one wonder just how much cash gets spent on keeping alive no-hope projects.